Bajaj Healthcare rises on getting nod to conduct Clinical Trial, Bioequivalence Study of Suvorexant Tablets
Bajaj Healthcare is currently trading at Rs. 419.60, up by 4.35 points or 1.05% from its previous closing of Rs. 415.25 on the BSE.
The scrip opened at Rs. 429.95 and has touched a high and low of Rs. 429.95 and Rs. 417.15 respectively. So far 9751 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 744.90 on 19-Mar-2025 and a 52 week low of Rs. 394.10 on 18-Dec-2025.
Last one week high and low of the scrip stood at Rs. 429.95 and Rs. 409.75 respectively. The current market cap of the company is Rs. 1327.44 crore.
The promoters holding in the company stood at 59.19%, while Institutions and Non-Institutions held 4.12% and 36.70% respectively.
Bajaj Healthcare has received approval from Central Drugs Standard Control Organisation (CDSCO) on December 31, 2025, to conduct Clinical Trial and Bioequivalence Study of Suvorexant Tablets.
Earlier, the company had received a positive recommendation from the Subject Expert Committee (Neurology & Psychiatry) of the CDSCO to initiate Phase III clinical trials for Suvorexant Tablets, available in strengths of 5mg, 10mg, 15mg, and 20mg.
Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.
